• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bright Green Announces Appointment of Seamus McAuley, Chief Operating Officer of Bright Green, as Chief Executive Officer

    2/9/23 8:30:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BGXX alert in real time by email

    Terry Rafih to remain as Executive Chairman of the Board

    Appointment reinforces Company's strategy to build out its team to deliver on the development of cannabis-based medicines and products, as well as its greenhouse expansion plans

    The Company confirms the receipt of its first funds from its EB-5 program

    GRANTS, N.M., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that it has appointed Chief Operating Officer (COO) Seamus McAuley as its new Chief Executive Officer (CEO). Mr. McAuley will succeed Terry Rafih, who will retain his role of Executive Chairman of the Board of Directors, after successfully leading and guiding Bright Green during a transformative time for the Company. Bright Green's executive management team currently reporting to Mr. Rafih will report to Mr. McAuley with immediate effect. The Company has also begun the process of retaining a search firm to support in the recruitment of key new executive roles.

    Throughout his 26-year career, Mr. McAuley has held several global senior leadership positions across the pharmaceutical, medical device and healthcare industries, including most recently as CEO of Alterola Biotech (OTC:ABTI), a U.K.-based pharmaceutical company focused on developing cannabinoid and cannabinoid-like medicines and products. His broad and diverse experience informs his commitment to Bright Green's strategy of botanical expertise, pharmaceutical development and medical cannabinoid product supply.

    Terry Rafih, executive chairman of the board of directors for Bright Green, said, "The Bright Green team and I are delighted to welcome Seamus to his new role as CEO. I am confident that, with his expertise in pharmaceuticals and product commercialization, he will successfully lead the execution of the next phase of Bright Green's strategy. Seamus is uniquely positioned to advance the many opportunities that lie ahead for the Company, including completing the buildout of and operating our state-of-the-art agricultural complex in Grants, New Mexico. His drug development and commercialization expertise is timely and will be particularly relevant as we engage with the U.S. Food and Drug Administration (FDA) on the clinical development of a number of molecules, as well as navigate the various regulatory frameworks applicable to our business moving forward."

    Mr. McAuley, CEO of Bright Green, said, "I am honored to have the opportunity to lead Bright Green through the next phase of our development and help drive the revenue generation that will result from the successful execution of our strategy. We have planned carefully to further create shareholder value and, pending approval and registration of our license with the U.S. Drug Enforcement Administration (DEA), Bright Green will be the only federally approved, publicly traded company focused on producing cannabis for the pharmaceutical industry in the U.S. With the development of our pharmaceutical assets, early engagement with the FDA and other global regulatory bodies, and the ability to supply both U.S. and global markets, I am excited about the potential of our portfolio and business, and look forward to sharing further updates in the weeks and months ahead."

    Lynn Stockwell, founder and board director of Bright Green, said, "The Board and I are thrilled to have Seamus serve as our new CEO. We have steadily built our business over the last several years, and we are confident that Seamus will successfully drive our strategy to become the premier federally authorized provider of cannabis and cannabis-derived products for the pharmaceutical industry. We are also incredibly grateful to Mr. Rafih for his work in getting Bright Green to this stage and we are excited to have his continued support and guidance in his continued role as Executive Chairman of the Board."

    This news follows Bright Green's announcement of its plans to raise $500 million under the United States Citizenship and Immigration Services' ("USCIS") EB-5 Program, an innovative vehicle for spurring investment and job creation in rural communities. USCIS administers the Program, under which investors, their spouses and unmarried children under 21 years of age are eligible to apply for a Green Card if they make the necessary investment in a commercial enterprise in the U.S. The Company has already started to build its pipeline of potential investors, comprising both individual applicants, as well as large international companies with a global workforce. Bright Green is also delighted to confirm that it has received funds from its first applications, confirming the proof of concept for the EB-5 program following the announcement last Wednesday. Further details on the Bright Green EB-5 program can be found by visiting our dedicated EB-5 website www.bgxxfasteb5.com. 

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include those related to our EB-5 Program capital raise. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") on March 29, 2022 and declared effective May 13, 2022, and in the Company's subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the company's results is included in the Company's SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov.

    About Bright Green

    Bright Green is one of the very few companies selected by the US government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Our conditional approval based on already agreed terms from the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us.

    Bright Green Media Contact

    [email protected]

    Bright Green Investor Relations Contact

    [email protected]

    Bright Green Information Deck



    Primary Logo

    Get the next $BGXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGXX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Green Corporation Announces the next steps for the completion of its restructuring plan

      FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement, Disclosure Statement and Plan. The highlights of the Plan and Disclosure will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the

      3/21/25 9:15:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances

      FORT LAUDERDALE, FLORIDA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on February 24, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement. The highlights of the RSA will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. The Company in its restructuring efforts has entered into an agreement with the DEA to immediately withdraw all Cannabis related renewal applications. This agreement will a

      2/24/25 9:15:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.

      The Company plans to emerge with federal loan guarantees for its 60 new mega farm owner/operators, that collectively will invest $3.5 billion to supply and strengthen the Drugs Made in America supply Chain. FORT LAUDERDALE, FLORIDA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on January 21, 2025, it has entered into a Restructuring Support Agreement (the "RSA") with Lynn Stockwell, a major shareholder of the Company (the "Plan Sponsor") to restructure the Company. To implement the terms of the RSA, the Company will file, and the Plan Sponsor will support the Company's Prepackaged Plan of Reorganization Under Chapte

      1/27/25 8:17:00 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Bright Green Corporation

      25-NSE - Bright Green Corp (0001886799) (Subject)

      3/21/25 11:19:49 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Bright Green Corp (0001886799) (Filer)

      3/21/25 9:15:14 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits

      8-K - Bright Green Corp (0001886799) (Filer)

      2/27/25 4:05:24 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Leadership Updates

    Live Leadership Updates

    See more
    • (Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

      Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

      1/14/24 10:00:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

      Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

      10/3/23 11:11:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Announces First Quarter 2023 Financial Update and Milestone Progress

      Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval. Commencement of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan. Company has raised short-term working Capital of $5.26m to commence its operations as it looks to capitalize on its historic DEA Registration in Q2 2023 and beyond. GRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Brig

      5/24/23 8:00:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Bright Green Corporation (Amendment)

      SC 13D/A - Bright Green Corp (0001886799) (Subject)

      9/6/23 5:19:19 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Bright Green Corporation

      SC 13D - Bright Green Corp (0001886799) (Subject)

      6/15/23 4:30:21 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Bright Green Corporation (Amendment)

      SC 13G/A - Bright Green Corp (0001886799) (Subject)

      6/12/23 5:28:12 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Elmasri Saleem sold $4,951 worth of shares (25,942 units at $0.19), decreasing direct ownership by 2% to 1,103,476 units (SEC Form 4)

      4 - Bright Green Corp (0001886799) (Issuer)

      9/11/24 4:05:11 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Elmasri Saleem sold $14,313 worth of shares (71,809 units at $0.20), decreasing direct ownership by 6% to 1,129,418 units (SEC Form 4)

      4 - Bright Green Corp (0001886799) (Issuer)

      9/10/24 4:05:08 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: Chief Executive Officer Singh Gurvinder was granted 5,500,000 shares (SEC Form 4)

      4/A - Bright Green Corp (0001886799) (Issuer)

      9/9/24 4:05:32 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care